ORIOLA OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.04 EUR | -0.95% |
|
-0.95% | -7.14% |
| 04-30 | Sweden’s Competition Watchdog Prohibits Oriola's Dose Dispensing Unit Sale | MT |
| 04-29 | ApotekstjÄNst Sverige Ab cancelled the acquisition of Svensk Dos AB. | CI |
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.11 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.14% | 192M | - | ||
| +18.74% | 71.7B | C+ | ||
| -3.62% | 23.73B | C+ | ||
| +10.27% | 9.01B | C | ||
| +11.24% | 8.72B | B | ||
| -18.91% | 8.29B | B- | ||
| +16.00% | 5B | B- | ||
| +17.83% | 4.48B | B+ | ||
| -2.11% | 4.08B | B- | ||
| -1.72% | 3.92B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- OKDBV Stock
- OKDAV Stock
- Ratings Oriola Oyj